Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,354 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The Impact of Positron Emission Tomography Imaging and Tumor Molecular Profiling on Risk Stratification, Treatment Choice, and Oncological Outcomes of Patients with Primary or Relapsed Prostate Cancer: An International Collaborative Review of the Existing Literature.
Sood A, Kishan AU, Evans CP, Feng FY, Morgan TM, Murphy DG, Padhani AR, Pinto P, Van der Poel HG, Tilki D, Briganti A, Abdollah F. Sood A, et al. Eur Urol Oncol. 2024 Feb;7(1):27-43. doi: 10.1016/j.euo.2023.06.002. Epub 2023 Jul 8. Eur Urol Oncol. 2024. PMID: 37423774 Review.
Testing the external validity of the POUT III trial (adjuvant platnium-based chemotherapy in upper tract urothelial carcinoma) in a North American cohort.
Corsi NJ, Stephens A, Finati M, Malchow T, Morrison C, Davis M, Hares K, Corsi MP, Arora S, Chiarelli G, Cirulli GO, Autorino R, Sood A, Rogers C, Abdollah F. Corsi NJ, et al. Among authors: sood a. Urol Oncol. 2024 Jun;42(6):175.e19-175.e25. doi: 10.1016/j.urolonc.2024.01.035. Epub 2024 Mar 23. Urol Oncol. 2024. PMID: 38522975 Clinical Trial.
The Role of Baseline Prostate-specific Antigen Value Prior to Age 60 in Predicting Lethal Prostate Cancer: Analysis of a Contemporary North American Cohort.
Finati M, Davis M, Stephens A, Chiarelli G, Cirulli GO, Morrison C, Affas R, Sood A, Buffi N, Lughezzani G, Briganti A, Montorsi F, Carrieri G, Rogers C, Vickers AJ, Abdollah F. Finati M, et al. Among authors: sood a. Eur Urol Oncol. 2024 Jul 10:S2588-9311(24)00172-X. doi: 10.1016/j.euo.2024.06.014. Online ahead of print. Eur Urol Oncol. 2024. PMID: 38991891
Impact of Prostate-Specific Antigen Screening Pattern on Prostate Cancer Mortality Among Non-Hispanic Black and Non-Hispanic White Men: A Large, Urban Health System Cohort Analysis.
Cirulli GO, Davis M, Stephens A, Chiarelli G, Finati M, Corsi N, Williams E, Affas R, Sood A, Buffi N, Lughezzani G, Carrieri G, Salonia A, Briganti A, Montorsi F, Rogers C, Abdollah F. Cirulli GO, et al. Among authors: sood a. J Urol. 2024 Oct;212(4):560-570. doi: 10.1097/JU.0000000000004118. Epub 2024 Jul 30. J Urol. 2024. PMID: 39079152
Radical cystectomy versus trimodal therapy for muscle-invasive bladder cancer: Analysis of an other-cause mortality matched cohort.
Finati M, Stephens A, Chiarelli G, Cirulli GO, Tinsley S, Wang Y, Sood A, Buffi N, Lughezzani G, Salonia A, Briganti A, Montorsi F, Busetto GM, Carrieri G, Rogers C, Abdollah F. Finati M, et al. Among authors: sood a. Urol Oncol. 2025 Jan;43(1):61.e1-61.e9. doi: 10.1016/j.urolonc.2024.08.001. Epub 2024 Sep 6. Urol Oncol. 2025. PMID: 39242301
3,354 results